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INTRODUCTION—There may be biologically relevant heterogeneity within typical late-onset 
Alzheimer’s dementia.
METHODS—We analyzed cognitive data from people with incident late-onset Alzheimer’s 
dementia from a prospective cohort study. We determined individual averages across memory, 
visuospatial functioning, language, and executive functioning. We identified domains with 
substantial impairments relative to that average. We compared demographic, neuropathology, and 
genetic findings across groups defined by relative impairments.
RESULTS—During 32,286 person-years of follow-up, 869 people developed Alzheimer’s 
dementia. There were 393 (48%) with no domain with substantial relative impairments. Some 
participants had isolated relative impairments in memory (148, 18%), visuospatial functioning 
(117, 14%), language (71, 9%), and executive functioning (66, 8%). The group with isolated 
relative memory impairments had higher proportions with APOE ε4, more extensive Alzheimer’s-
related neuropathology, and higher proportions with other Alzheimer’s dementia genetic risk 
variants.
DISCUSSION—A cognitive subgrouping strategy may identify biologically distinct subsets of 
people with Alzheimer’s dementia.
Keywords
Alzheimer’s disease; cognition; subgroups; endophenotypes; heterogeneity; genetics; 
neuropathology
1. Introduction
There may be considerable heterogeneity in clinical presentation among people with 
incident Alzheimer’s dementia begging the question of whether Alzheimer’s dementia in 
older adults should be considered a single entity or meaningfully subdivided into distinct 
disorders. Meaningfully subdividing a condition into distinct groups is essential to the 
strategy of personalized medicine1–3. Data are currently lacking demonstrating a scalable 
approach for meaningfully subdividing Alzheimer’s dementia.
Recent proposed guidelines identified atypical Alzheimer’s disease subtypes usually having 
younger age of onset, including logopenic primary progressive aphasia, dysexecutive 
Alzheimer’s disease, and posterior cortical atrophy4. Intriguingly, each of these subtypes is 
associated with prominent impairment in a single non-memory domain – language, 
executive functioning and visuospatial functioning, respectively – with relatively intact 
memory performance. These previously identified atypical Alzheimer’s disease subtypes 
may represent extremes of a spectrum of disease phenotypy.
We followed insights from neuropsychology, where practitioners have considered patterns of 
relative impairments across cognitive domains to facilitate diagnosis since the earliest days 
of the field5. We used cognitive data to determine the distribution at Alzheimer’s dementia 
diagnosis for memory, language, executive functioning, and visuospatial abilities in a 
community-based prospective cohort study. We determined individual averages across 
domains, and identified domains with substantial impairments relative to that average. We 
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defined subgroup membership based on which domains had relative impairments. We 
compared demographic, neuropathology, and genetic findings across subgroups to test the 
hypothesis that we could use cognitive data to identify biologically distinct late-onset 
Alzheimer’s dementia subgroups.
2. Methods
We followed the STROBE guidelines (Appendix A)6. All steps are summarized in Appendix 
B.
2.1. Study population
The source population for the Adult Changes in Thought (ACT) study consists of 
community-living members of Group Health, a health maintenance organization in western 
Washington State. A random sample of community-living Group Health members ≥65 years 
old without established dementia diagnoses was invited to an enrollment visit in 1994–1996. 
The Cognitive Abilities Screening Instrument (CASI) was administered. The CASI is a 100-
point scale that assesses several cognitive domains. Individuals with scores >85 were invited 
to enroll. Those with scores of ≤85 were further evaluated with a neuropsychological battery 
and comprehensive neurological evaluation. The neuropsychological battery included clock 
drawing7, verbal fluency8, Mattis Dementia Rating Scale9, Boston naming8, verbal paired 
associations and recall, logical memory and recall10, Word List Memory8, Constructional 
Praxis and recall8, Trails A and B11, and Information and Comprehension subtest items10.
All cognitive and clinical data were reviewed in a multidisciplinary consensus conference to 
determine dementia status; data from each case are discussed and forms with standardized 
criteria are filled out. Composite scores were not available at the time of consensus 
conferences and were not considered. Individuals free of dementia were invited to enroll in 
the longitudinal study. Identical methods were used for an expansion cohort in 2000–2003. 
In 2005 the study began continuous enrollment in which identical methods are used to enroll 
new participants each month. This report considers all enrollees through April 2015, the 
most recent data freeze.
Once enrolled, participants are administered the CASI every two years. The same 
procedures are used to identify incident dementia12 and probable or possible Alzheimer’s 
disease using NINCDS-ADRDA criteria13, referred to here as Alzheimer’s dementia.
Other than being a Group Health member, being free of dementia, and volunteering for a 
longitudinal study, there are no additional inclusion or exclusion criteria for ACT. ACT 
evaluates participants in their own homes or at a study clinic for study visits14.
We focus here on individuals who developed incident Alzheimer’s dementia. The derivation 
of the analytic cohort is provided in Figure 1. The study was reviewed by Group Health and 
University of Washington Institutional Review Boards. Participants gave written informed 
consent.
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2.2. Ascertainment of subgroups
An expert panel (ET, AS, and JM) considered each cognitive item and assigned each item to 
a single cognitive domain – memory, visuospatial functioning, language, executive 
functioning, or other. We used modern psychometric methods to obtain scores for each 
domain. Composite scores have been recommended to address idiosyncrasies of individual 
cognitive tests. Modern psychometric approaches have proven to have incrementally better 
validity data than scores derived from standard approaches15–17, and they are specifically 
recommended for genetic analyses18. We re-coded observed item responses to avoid sparse 
response categories and limit to ≤10 response categories (see Appendix C–F). We used 
Mplus 7.419 to fit confirmatory factor analysis single factor or bifactor models for each 
domain separately. All scores were scaled to have mean 0 and standard deviation (SD) 1 in 
all those with incident AD who had all four scores (n=825). Psychometric modeling details 
for each domain are provided in Appendix C–F.
We determined each person’s average across the four cognitive domain scores. We 
determined relative impairments by calculating differences between each domain score and 
the individual’s average cognition score across domains. We evaluated candidate thresholds 
to define “substantial” relative impairments ranging from 0.40 to 1.25 points at 0.05-point 
increments. For each candidate threshold, we classified people as having 0, 1, or ≥2 domains 
with substantial relative impairments; we further divided those with 1 domain according to 
which domain was relatively impaired. This approach is illustrated in Box 1, where we 
analyze domain scores for a made-up person and for two real people from ACT diagnosed 
with atypical Alzheimer’s disease using the same methods described above. We further 
illustrate performance on a single selected test from each domain in Box 2.
As discussed in Appendix G, we empirically selected a threshold of 0.75 points. We 
compared characteristics of groups defined by that threshold.
2.3. Neuropathology procedures
ACT Neuropathology protocols are published20,21. We evaluated neurofibrillary tangles as 
measured by Braak stage22, neuritic plaque frequency according to CERAD23, presence of 
cerebral amyloid angiopathy, presence of hippocampal sclerosis, presence and location of 
Lewy bodies categorized as present anywhere and as present in the amygdala, presence of 
cystic infarcts, and presence and location of cerebral microinfarcts categorized as present 
anywhere, in the cortex, or in deep structures (basal ganglia or thalamus). We present 
findings for the group of ACT participants who died free of dementia, for everyone who died 
following diagnosis of Alzheimer’s dementia, and separately for those in each cognitively 
defined subgroup. ACT does not identify people with mild cognitive impairment (MCI); 
people who died free of dementia could include some people with MCI. The neuropathology 
results presented here exclude people who died with non-Alzheimer’s dementia.
2.4. Genetic data
APOE genotyping was available for most participants24. ACT participants with European 
ancestry were included in the Alzheimer’s Disease Genetics Consortium (ADGC)24 and the 
International Genomics of Alzheimer’s Project (IGAP)25 meta-analyses of genome-wide 
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single nucleotide variant (SNV) associations with late-onset Alzheimer’s dementia. 
Genotyping, quality control, and imputation procedures are detailed in those publications. 
We used imputed genotype dosage data for the SNV with the highest level of association at 
each of the 20 loci that achieved genome-wide significance in the Lambert et al. IGAP 
paper25 (“IGAP SNVs”).
2.4. Statistical analyses
Group differences in descriptive findings were compared using linear or logistic regression, 
as appropriate, and a categorical group variable with “no domain” identified as the reference. 
We used similar models for autopsy findings, controlling for age at death, sex, and years of 
education.
For genetic analyses, we used non-demented elderly individuals from ACT as the reference 
group (some of these individuals could have had MCI), and included terms for age, sex, and 
three principal components to account for population stratification. As in26, we did not 
adjust for APOE genotype. We determined odds ratios for each IGAP SNV for all people 
with Alzheimer’s dementia, and separately for each cognitively-defined subgroup.
3. Results
3.1. Characteristics of individuals with incident Alzheimer’s dementia
As of April 2015 ACT had enrolled 5,088 people, of whom 4,365 had at least one follow-up. 
Over 32,286 person-years of follow-up (mean 8.1) 1,076 people developed dementia12, of 
which 869 developed probable or possible Alzheimer’s disease by NINCDS-ADRDA 
criteria13, referred to here as Alzheimer’s dementia. We had sufficient data to compute all 
four cognitive domain scores for 825 (95%) of these; most of the remainder had only a 
phone-based CASI without visuospatial functioning assessment.
On average people with Alzheimer’s dementia performed much worse than people with 
normal cognition, especially for memory; see Box 2 for examples of test scores (one per 
domain) alongside published normative data27,28. We used means and standard deviations 
from the 825 people from ACT with incident Alzheimer’s dementia and all four domain 
scores to define the metric (mean=0, SD=1) for each domain.
We identified a threshold of 0.75 points as a threshold indicating substantial relative 
impairment (See Appendix G). At that threshold, there were 393 people (48%) who had no 
domains with a substantial relative impairment. There were 396 people (48%) with a 
substantial relative impairment in a single domain, including 148 with a substantial relative 
impairment in memory (18%), 117 in visuospatial functioning (14%), 71 in language (9%), 
and 66 in executive functioning (8%). The remaining 30 people (4%) had substantial relative 
impairments in ≥2 domains.
Demographic characteristics of people with incident Alzheimer’s dementia in each 
cognitively-defined subgroup are shown in Table 1, along with APOE genotype and 
cognitive data. There were no important differences across groups in demographic 
characteristics, including age at dementia onset. There were substantial differences in the 
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proportion of people with incident Alzheimer’s dementia who had at least one APOE ε4 
allele, ranging from 45% of those with isolated relative memory impairment to 22% of those 
with isolated relative executive functioning impairment; the overall χ2 p-value for APOE 
was 0.005.
Averages for cognitive scores are also shown in Table 1. For most groups, average CASI 
total scores were similar to the overall average for people with incident Alzheimer’s 
dementia, though they were somewhat higher for people with relative visuospatial 
functioning impairments (p=0.01) and perhaps somewhat lower for those with relative 
executive functioning impairments (p=0.61) and especially those with multiple domains with 
relative impairments (p=0.02). The CASI total score includes 10 points for visuospatial 
functioning and 12 points for executive functioning, so 10% of the total score is based on 
executive functioning and 12% on executive functioning, while our average scores included 
other measures of these domains and also assigned each of them to 25% of the total average 
score.
By design, average scores across the entire group of people with incident Alzheimer’s 
dementia for each cognitive domain were 0 with SD=1. People with no domains with a 
substantial relative impairment had average overall scores and average domain scores that 
reflected these patterns. The four groups made up of people with a single domain with 
relative impairments had mean scores for the indicator domain about a full standard 
deviation below average (about −1.0), while scores for the other domains were close to the 
average (about 0.0) or a little better than the average. On average, the group with multiple 
domains with relative impairments had lower scores on non-memory domains.
3.2. Autopsy findings
Autopsy findings are summarized in Table 2. Of the 825 people with incident Alzheimer’s 
dementia and all four cognitive domain scores, 180 had died and come to autopsy at the time 
of this report. We evaluated data from those individuals and people who died without a 
diagnosis of dementia; people with non-Alzheimer’s dementia are not included in Table 2.
Most neuropathological findings were more common among people with Alzheimer’s 
dementia than people with no dementia (all p <0.023, with the exception of Lewy bodies). 
The frequency and mean severity of most neuropathological findings were similar across 
cognitively-defined subgroups. Having a Braak stage of IV or higher was more common 
among people with substantial relative memory impairment (91%) than among everyone 
else with Alzheimer’s dementia (68%, p=0.003), and the proportion of people with amyloid 
angiopathy was also higher, though this did not meet the traditional statistical significance 
threshold (50% vs. 35%, p = 0.08).
3.3. Genetic findings
Genetic findings are summarized in Table 3. The fifth column of Table 3 shows odds ratios 
(ORs) for the association between the 20 SNVs reported in Lambert et al.25 and Alzheimer’s 
dementia case-control status in ACT. In general, findings in ACT were similar to those 
previously reported25. The remaining 6 columns of Table 3 show ORs for the associations 
between the 20 IGAP SNVs and case-control status, where “cases” were limited to 
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individuals in a cognitively-defined subgroup. While we were underpowered for genetic 
association analyses with data from a single study, we nevertheless marked “extreme risk 
ORs” (defined as OR>1.30) in shades of red, and “extreme protective ORs” (defined as 
OR<1/1.30~0.77) in shades of blue.
ORs for those with no domain with substantial relative impairments were broadly similar to 
those for the entire group of people with Alzheimer’s dementia, though there were 
somewhat smaller ORs for the SNV associated with CR1 and MS4A6A, and somewhat 
larger ORs for the SNVs associated with ABCA7 and CD33. For the subgroups of 
individuals with a single domain with a substantial relative impairment, findings were quite 
heterogeneous. There were eight extreme risk ORs for the group with an isolated relative 
memory impairment. There were nine extreme risk ORs (6 risk, 3 protective) for the group 
with an isolated relative visuospatial functioning impairment, and nine extreme risk ORs for 
the group with an isolated substantial language impairment (4 risk, 5 protective). There were 
six extreme risk ORs for the group with an isolated relative executive functioning 
impairment (4 risk, 2 protective). The small group with multiple domains with relative 
impairments had fifteen extreme risk ORs (nine risk, 5 protective).
There were several SNVs with extreme protective ORs for at least one cognitively defined 
subgroup (blue cells) and extreme risk ORs for at least one other subgroup (red cells), 
including SNVs associated with SORL1, FERMT2, CASS4, PTK2B, ZCWPW1, and 
NME8.
4. Discussion
4.1. Key findings
We developed and implemented an approach to identify subgroups of people with typical 
late-onset Alzheimer’s dementia on the basis of cognitive test data. We generated scores for 
four domains – memory, visuospatial functioning, language, and executive functioning – and 
characterized variation in these scores in a large group of people with incident Alzheimer’s 
dementia. We determined each individual’s average level of cognition at Alzheimer’s 
dementia diagnosis. We then determined differences from this average to identify domain(s) 
with substantial relative impairments. About half of people with incident Alzheimer’s 
dementia had no domains with a substantial relative impairment, and a similar number of 
people had a single domain with a substantial relative impairment.
Demographic characteristics were similar across each of the cognitively defined subgroups, 
including age at the time of Alzheimer’s dementia diagnosis. This point emphasizes a 
distinction with the atypical Alzheimer’s disease subtypes such as posterior cortical atrophy 
and primary progressive aphasia identified by the International Working Group4; each of 
these is described as having an earlier age of onset than is typical for late-onset Alzheimer’s 
dementia, and certainly earlier age of onset than the mid to late 80s as we found for each 
subgroup and overall (see Table 1). These atypical Alzheimer’s disease subtypes may 
occasionally be found in older adults, as demonstrated by the fact that there was one person 
each with posterior cortical atrophy and with primary progressive aphasia in ACT (see Box 
1). Our approach to categorizing people with typical late-onset Alzheimer’s dementia, when 
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applied to those individuals with previously defined atypical Alzheimer’s disease subtypes, 
worked precisely as one would wish – the person with posterior cortical atrophy had an 
intact memory score and a substantial relative impairment in visuospatial functioning, while 
the person with primary progressive aphasia had an intact memory score and a substantial 
relative impairment in language (see Box 1). Additional analyses will be necessary to 
determine relationships between people diagnosed with PPA, PCA, and dysexecutive 
Alzheimer’s disease and people we identify with isolated substantial relative impairments in 
language, visuospatial functioning, and executive functioning.
The group with isolated substantial memory impairment stood out from the other groups. 
Using only cognitive testing data for our group assignments, we identified this group of 18% 
of all people with incident late onset Alzheimer’s dementia who had a higher proportion 
with APOE ε4 alleles (45% compared with 34% for everyone with Alzheimer’s dementia), a 
higher proportion with Braak stage ≥4 (indeed, 91% of this group had Braak stage ≥4), and a 
higher proportion with amyloid angiopathy. Furthermore, this group had eight of the IGAP 
SNVs with ORs ≥1.30 – and they were all in the risk direction (all shades of red in Table 3). 
Further analyses of this group are warranted.
The other subgroups appeared to be readily distinguishable from the group with isolated 
substantial memory impairment and in terms of the pattern of findings across the SNVs they 
were also distinguishable from each other. Larger sample sizes will be needed to make 
firmer conclusions about those groups.
4.2. Possible explanations for findings
One possible explanation for these findings is that the strategy we implemented to group 
people based on relative cognitive impairments works to identify biologically distinct 
Alzheimer’s dementia subtypes. This explanation seems particularly well buttressed for the 
group with substantial relative impairments in memory, where APOE genotype, Braak stage, 
and seven IGAP SNVs had extreme ORs, all in the risk direction. The genetic data also 
suggest support for possible biological relevance for the group with substantial relative 
impairments in visuospatial functioning, where there were eleven IGAP SNVs with extreme 
ORs.
Another possibility is that our observations do not reflect biologically distinct groups and 
instead represent the play of chance. Replication in other samples will be very important to 
differentiate between these two possibilities.
4.3. Implications of findings
If these findings are replicated in other samples, they suggest that a non-invasive, widely-
available technology – cognitive testing – may differentiate people with Alzheimer’s disease 
into biologically relevant distinct subgroups. In the future, combinations of cognitive testing 
alongside other modalities such as structural MRI, CSF biofluids, or PET scans may be used 
to identify subgroups of people with similar biological processes that are distinct from those 
of people in other subgroups. Much work remains to be done; we are hopeful this work 
represents initial steps towards a personalized medicine approach to Alzheimer’s dementia 
therapeutics.
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4.4. Strengths and limitations
The ACT study includes a sample that reflects the demographic characteristics of the 
surrounding community. We chose to categorize people based on data at their initial 
Alzheimer’s dementia diagnosis, so disease duration (and thus likely severity) should not 
vary much, though there may be differences in severity across subgroups even within this 
timeframe. The sample is limited in terms of ethnic heterogeneity; the genetic analyses are 
limited by design to people with European ancestry. The genetic findings are based on a 
relatively small number of study participants. Replication in additional study samples will be 
important. We were unable to evaluate differences in imaging parameters or in rates of 
cognitive change over time with the data available to us.
We evaluated heterogeneity among people with clinical Alzheimer’s dementia based on 
NINCDS-ADRDA criteria. It has long been appreciated that there is an imperfect correlation 
between Alzheimer’s pathology and diagnoses of dementia and Alzheimer’s dementia, and 
that other forms of pathology such as vascular brain disease play important roles29. We 
found some differences in autopsy findings across cognitively-defined Alzheimer’s dementia 
subgroups. Larger samples with autopsy data will be needed to more definitively investigate 
the roles disparate neurodegenerative conditions may play in the heterogeneity of clinical 
presentation.
The categorization scheme we developed borrows from principles that have been 
instrumental in clinical neuropsychology for many years, since it considers patterns of 
impairments, compared in this case to an individual’s overall ability level (as opposed to 
their estimated premorbid ability). This approach successfully detected the individuals 
diagnosed with primary progressive aphasia and posterior cortical atrophy from the ACT 
study (see Box 1). These individuals can be considered “positive controls” to demonstrate 
the success of the categorization approach. The categorization scheme is based entirely on 
cognitive data, which is well tolerated and non-invasive. Most of our missing data were for 
visuospatial functioning; people with visual impairments severe enough that their 
visuospatial functioning cannot be assessed cannot be categorized using this approach. 
Furthermore, the visuospatial functioning domain was limited by the data we had available 
to form our composite scores. Future studies could investigate use of standard rather than 
modern psychometric approaches to determine subgroup membership.
We used theory-driven approaches to categorize people with late-onset Alzheimer’s 
dementia rather than computer-driven approaches such as cluster analysis. Cluster analysis 
assigns people to categories that maximize distinctions between classes of people and result 
in categories that may reflect clinical experience but also may not. Subsequent research 
could compare our findings to those that would have been obtained with cluster analysis 
approaches.
4.5. Conclusions
Here we describe development and implementation of an approach to categorize people at 
the time of Alzheimer’s dementia diagnosis based on patterns of memory, visuospatial 
functioning, language, and executive functioning. About half of those incident Alzheimer’s 
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dementia had a single domain with a substantial relative impairment. Initial findings provide 
some support for the notion that these subgroups may be biologically distinct. Further work 
will be needed to replicate these findings.
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Box 1
Illustration of cognitively defined subgroup procedures
We determined scores for memory, visuospatial functioning, language, and executive 
functioning. We determined each person’s average across domains at dementia diagnosis. 
We determined differences from individual average scores.
Our first example case is a hypothetical individual:
Memory
Visuospatial
functioning Language
Executive
functioning
Scores 0.00 0.00 0.00 −1.00
Average −0.25 −0.25 −0.25 −0.25
Difference +0.25 +0.25 +0.25 −0.75
This person scored at the ACT average among people with Alzheimer’s dementia for 
memory, visuospatial functioning, and language, and scored 1 SD below average for 
executive functioning (top row). This produces an average score of −0.25 (second row). 
The third row shows differences from average for each domain, with a difference of 
−0.75 for executive functioning, which would lead this person to be categorized in the 
substantial executive functioning impairment subgroup.
Our second example case was a real individual with scores as shown below:
Memory
Visuospatial
functioning Language
Executive
functioning
Scores +1.02 −0.12 −1.02 −0.19
Average −0.08 −0.08 −0.08 −0.08
Difference +1.10 −0.04 −0.94 −0.11
This person’s average score was −0.08. Her memory score was quite a bit better than this, 
while her language score was substantially worse (difference of −0.94 points). At the 
ACT consensus conference, she was diagnosed with primary progressive aphasia, a 
previously identified atypical Alzheimer’s disease subtype characterized by intact 
memory and a substantial language impairment.
Our third example case was another real individual with scores as shown below:
Memory
Visuospatial
functioning Language
Executive
functioning
Scores +2.00 +0.21 +1.39 +0.26
Average +0.96 +0.96 +0.96 +0.96
Difference +1.04 −0.75 +0.44 −0.70
This person’s average score was +0.96. His memory score and language score were 
higher than his executive functioning and visuospatial functioning scores. He was 
diagnosed with posterior cortical atrophy, another previously identified atypical 
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Alzheimer’s disease subtype characterized by intact memory and a substantial 
visuospatial functioning impairment.
These examples demonstrate procedures used to determine cognitively-defined subgroups 
of typical late-onset Alzheimer’s dementia. The real examples show how these 
approaches work for one individual each with previously established atypical 
Alzheimer’s disease subtypes.
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Box 2
Performance of people with Alzheimer’s dementia from the ACT study 
compared to published normative data
Memory: 
Logical 
Memory 
II from 
the 
WMS-R1 Visuospatial Construction2 Language: Animal Fluency2
Executive 
functioning: 
Trails B2
Raw Score Norms, Previously Published
Normal, 25th percentile 8 – 9 8.9 12.4 198
Normal, 50th percentile 1 1 – 13 10.2 15.3 150
Normal, 75th percentile 1 6 10.9 18.5 109
Mean (SD) from people from ACT with incident Alzheimer’s dementia
All with AD 1.7 (2.6) 8.8 (1.7) 10.5 (3.9) 231*
 0 domains with relative 
impairment
1.4 (2.1) 8.9 (1.4) 10.4 (3.6) 257*
 1 domain with relative impairment
  Memory 0.1 (0.7) 9.7 (1.2) 10.7 (4.0) 166 *
  Visuospatial 2.7 (3.1) 7.2 (2.0) 12.0 (4.2) 230 *
  Language 3.2 (3.2) 9.3 (1.4) 8.8 (3.5) 225 *
  Executive functioning 3.6 (3.2) 9.2 (1.3) 8.8 (3.3) 300*
 ≥ 2 domains with 
relative impairment
3.5 (3.4) 8.0 (2.9) 10.8 (4.5) 300*
*Trails B is terminated at 5 minutes (300 seconds). The median and 25th percentile for everyone with Alzheimer’s dementia and for each 
of the subgroups was 300 seconds (it was 296 seconds for the group with single domain – memory). For example, for everyone with 
Alzheimer’s dementia, the 25th percentile was 300, and the median was 300, while the 75th percentile was 231. We thus show only the 75th 
percentile for people with Alzheimer’s dementia from ACT.
This table shows published normative data and data from people with incident 
Alzheimer’s dementia from the ACT study for one indicator from each domain. For the 
memory domain, scores for people with Alzheimer’s dementia are substantially lower on 
Logical Memory II than published normative data for people over age 83 (median age 
88)1. The group with substantial relative memory impairment had the very lowest 
performance, as expected. For the other three tests, we show published data from 
cognitively intact females aged 85–89 with >12 years education2, which is the modal 
group for the ACT study. In the visuospatial functioning domain, construction was not 
especially impaired for people with Alzheimer’s dementia compared with published 
normative data, with the exception of the people with substantial relative visuospatial 
functioning impairments. In the language domain, animal naming was substantially 
impaired compared with published normative data across all groups of people with 
Alzheimer’s dementia, and most profoundly among those with substantial relative 
language impairments, but also among those with substantial relative executive 
functioning impairments. In the executive functioning domain, Trails B was 300 seconds 
(maximum value) for more than half of people with Alzheimer’s dementia in the ACT 
study, and for at least three quarters of those in the isolated substantial executive 
functioning group and the group with more than 1 domain with a substantial impairment.
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Research in Context
1. Systematic review: We reviewed PubMed literature sources on 
endophenotyping in the context of Alzheimer’s dementia. We found many 
papers on fluid and neuroimaging biomarker strategies, but none that 
incorporated patterns of cognitive tests. We have contributed to the literature 
considering differences between memory and executive functioning among 
people with Alzheimer’s dementia to isolate people with prominent executive 
dysfunction. We are not aware of studies that have also considered language 
and visuospatial functioning as well.
2. Interpretation: Our findings indicate that our cognitive subtyping strategy 
identified groups that had heterogeneous neuropathological findings and 
disparate relationships with genetic variants previously identified to be 
associated with risk for late-onset Alzheimer’s dementia.
3. Future directions: Future research is needed to replicate these findings in 
other populations and determine whether a cognitive subtyping strategy may 
be useful to isolate biologically relevant subsets of people with Alzheimer’s 
dementia and thus used as an endophenotyping strategy
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Figure 1. 
Derivation of the analytic sample.
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